Ivermectin for preventing and treating COVID-19
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of action suggests an inhibitory effect on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) replication in the early stages of infection. Currently, evidence on efficacy and safety of ivermectin for prevention of SARS‐CoV‐2 infection and COVID‐19 treatment is conflicting. Objectives To assess the efficacy and safety of ivermectin compared to no treatment, standard of care, placebo, or any other proven intervention for people with COVID‐19 receiving treatment as inpatients or outpatients, and for prevention of an infection with SARS‐CoV‐2 (postexposure prophylaxis). Search methods We searched the Cochrane COVID‐19 Study Register, Web of Science (Emerging Citation Index and Science Citation Index), medRxiv, and Research Square, identifying completed and ongoing studies without language restrictions to 26 May 2021. Selection criteria We included randomized controlled trials (RCTs) comparing ivermectin to no treatment, standard of care, placebo, or another proven intervention for treatment of people with confirmed COVID‐19 diagnosis, irrespective of disease severity, treated in inpatient or outpatient settings, and for prevention of SARS‐CoV‐2 infection. Co‐interventions had to be the same in both study arms. We excluded studies comparing ivermectin to other pharmacological interventio…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“its authors developed a Research Integrity Assessment (RIA) tool, a hierarchical, six-domain framework applied during eligibility screening, before risk-of-bias assessment”
From Artificial intelligence to enhance research integrity in evidence-based medicine: toward scalable trustworthiness assessment (2026) · cites this paper as Popp et al., 2022
In the citing paper
“In the resulting Cochrane synthesis after RIA screening, ivermectin showed no clear mortality benefit compared to standard of care or placebo, with confidence intervals crossing 1”
From Artificial intelligence to enhance research integrity in evidence-based medicine: toward scalable trustworthiness assessment (2026) · cites this paper as Popp et al., 2022
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Self-citationDexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Remdesivir for the Treatment of Covid-19 — Final Report
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., Chu, H. Y., Luetkemeyer, A., Kline, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2007764 · Cited by 7,267
Factors associated with COVID-19-related death using OpenSAFELY
Williamson, E. J., Walker, A. J., Bhaskaran, K., Bacon, S., Bates, C., Morton, C. E., Curtis, H. J., Mehrkar, A., Evans, D., Inglesby, P., et al. (2020) · Nature · doi:10.1038/s41586-020-2521-4 · Cited by 6,674
Plea for routinely presenting prediction intervals in meta-analysis.
IntHout, J., Ioannidis, J. P. A., Rovers, M. M., & Goeman, J. J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010247 · Cited by 2,264
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly, L., Druce, J. D., Catton, M. G., Jans, D. A., & Wagstaff, K. M. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104787 · Cited by 2,179
Research works printed but not linked: 9
- Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane Available from www.training.cochrane.org/handbook
- Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook
- Higgins JP Savović J Page MJ Elbers RG Sterne JA Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook
- Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook · DOI · Paper page
- Hill A Abdulamir A Ahmed S Ashgar A Basri E Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection Research Square [preprint] 10.21203/rs.3.rs-148845/v1 · DOI
- Lefebvre C Glanville J Briscoe S Littlewood A Marshall C Metzendorf MI Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from: www.training.cochrane.org/handbook
- Oran DP The proportion of SARS-CoV-2 infections that are asymptomatic: a systematic review Annals of Internal Medicine M20 6976 10.7326/M20-6976 · DOI · Paper page
- Review Manager Web (RevMan Web) Cochrane 2020
- Schünemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020 Available from www.training.cochrane.org/handbook
Cited by
Koc, H. C., Xiao, J., Liu, W., Li, Y., & Chen, G. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.75056 · Cited by 282
Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.
Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201662 · Cited by 242
Artificial Intelligence in Biological Sciences
Bhardwaj, A., Kishore, S., & Pandey, D. K. (2022) · Life · doi:10.3390/life12091430 · Cited by 210
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
Self-citationIvermectin for preventing and treating COVID-19
Popp, M., Stegemann, M., Metzendorf, M.-I., Gould, S., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub2 · Cited by 167
Self-citationLim, S. C. L., Hor, C. P., Tay, K. H., Jelani, A. M., Tan, W. H., Ker, H. B., Chow, T. S., Zaid, M., Cheah, W. K., Lim, H. H., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.0189 · Cited by 131
COVID‐19 in Latin America and the Caribbean: Two years of the pandemic
Schwalb, A., Armyra, E., Méndez‐Aranda, M., & Ugarte‐Gil, C. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13499 · Cited by 88
Drug-Induced Liver Injury in COVID-19 Patients: A Systematic Review
Sodeifian, F., Seyedalhosseini, Z., Kian, N., Eftekhari, M., Najary, S., Mirsaeidi, M. S., Farsi, Y., & Nasiri, M. J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.731436 · Cited by 73
Data capture and sharing in the COVID-19 pandemic: a cause for concern
Dron, L., Kalatharan, V., Gupta, A., Häggström, J., Zariffa, N. M.-D., Morris, A. D., Arora, P., & Park, J. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00147-9 · Cited by 70
Buonfrate, D., Chesini, F., Martini, D., Roncaglioni, M. C., Fernandez, M. L. O., Alvisi, M. F., Simone, I. D., Rulli, E., Nobili, A., Casalini, G., et al. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106516 · Cited by 66
Marcolino, M. S., Meira, K. C., Guimarães, N. S., Motta, P. P., Chagas, V. S., Kelles, S. M. B., de Sá, L. C., Valácio, R. A., & Ziegelmann, P. K. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07589-8 · Cited by 59
Practical recommendations to communicate with patients about health‐related conspiracy theories
Marques, M. D., Douglas, K. M., & Jolley, D. (2022) · The Medical Journal of Australia · doi:10.5694/mja2.51475 · Cited by 41
Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer
Elkrief, A., Wu, J. T.-Y., Jani, C., Enriquez, K. T., Glover, M. J., Shah, M. R., Shaikh, H. G., Beeghly-Fadiel, A. C., French, B. C., Jhawar, S. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1368 · Cited by 39
Wang, J., Levi, J., Ellis, L., & Hill, A. M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab581 · Cited by 39
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Ho, W. S., Zhang, R., Tan, Y. L., & Chai, C. L. L. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106201 · Cited by 37
Menéndez, J. C. (2022) · Molecules · doi:10.3390/molecules27030658 · Cited by 36
Izcovich, A., Peiris, S., Ragusa, M., Tortosa, F., Rada, G., Aldighieri, S., & Reveiz, L. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.12.018 · Cited by 32
Hayward, G., Yu, L.-M., Little, P., Gbinigie, O., Shanyinde, M., Harris, V., Dorward, J., Saville, B. R., Berry, N., Evans, P. H., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106130 · Cited by 31
A Comprehensive Review on the Efficacy of Several Pharmacologic Agents for the Treatment of COVID-19
Haddad, F., Dokmak, G., & Karaman, R. (2022) · Life · doi:10.3390/life12111758 · Cited by 27
SARS CoV-2 Seroprevalence in Selected States of High and Low Disease Burden in Nigeria
Kolawole, O. M., Tomori, O., Agbonlahor, D. E., Ekanem, E., Bakare, R. A., Abdulsalam, N., Okojie, O. H., Braide, E. I., Uzochukwu, B. S. C., Rafindadi, A., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.36053 · Cited by 26
Recommendations on the in-hospital treatment of patients with COVID-19
Kluge, S., Malin, J. J., Fichtner, F., Müller, O. J., Skoetz, N., & Karagiannidis, C. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0374 · Cited by 25
Self-citationMohamed, Y., El‐Maradny, Y. A., Saleh, A. K., Nayl, A. A., El‐Gendi, H., & El‐Fakharany, E. M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113499 · Cited by 23
An Overview of Repurposed Drugs for Potential COVID-19 Treatment
Govender, K., & Chuturgoon, A. A. (2022) · Antibiotics · doi:10.3390/antibiotics11121678 · Cited by 23
Singh, S., Boyd, S., Schilling, W. H., Watson, J. A., Mukaka, M., & White, N. J. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae045 · Cited by 22
From standard systematic reviews to living systematic reviews
Breuer, C., Meerpohl, J. J., & Siemens, W. (2023) · Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen · doi:10.1016/j.zefq.2022.11.007 · Cited by 21
Sansone, N. M. S., Boschiero, M. N., & Marson, F. A. L. (2024) · Biomedicines · doi:10.3390/biomedicines12102206 · Cited by 21
Clinical update on COVID-19 for the emergency and critical care clinician: Medical management
Long, B., Chavez, S., Carius, B. M., Brady, W. J., Liang, S. Y., Koyfman, A., & Gottlieb, M. A. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.03.036 · Cited by 21
Chen, Y., & Chi, C. (2023) · Dermatologica Sinica · doi:10.4103/ds.ds-d-23-00159 · Cited by 20
Dilokpattanamongkol, P., Yan, C., Jayanama, K., Ngamjanyaporn, P., Sungkanuparph, S., & Rotjanapan, P. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04393-6 · Cited by 19
Inappropriate use of ivermectin during the COVID-19 pandemic: primum non nocere!
Barac, A. M., Bartoletti, M., Azap, Ö. K., Bussini, L., Ergönül, Ö., Krause, R., Paño‐Pardo, J. R., Power, N. R., Rodríguez‐Baño, J., Sibani, M., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.03.022 · Cited by 19
COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
Bostanghadiri, N., Ziaeefar, P., Mofrad, M. G., Yousefzadeh, P., Hashemi, A., & Darban‐Sarokhalil, D. (2023) · BioMed Research International · doi:10.1155/2023/1879554 · Cited by 18
Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
Spanakis, M., Patelarou, A. E., Patelarou, E., & Tzanakis, Ν. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111711 · Cited by 18
Ivermectin for treatment of COVID-19: A systematic review and meta-analysis
Song, Z., Shi, S., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27647 · Cited by 17
Ivermectin: A Controversial Focal Point during the COVID-19 Pandemic
Castillejos-López, M. D. J., Espíndola, L. M. T., Huerta‐Cruz, J. C., Flores‐Soto, E., Romero-Martínez, B. S., Velázquez‐Cruz, R., Higuera-Iglesias, A. L., Camarena, Á., Torres-Soria, A. K., Salinas‐Lara, C., et al. (2022) · Life · doi:10.3390/life12091384 · Cited by 17
Honey as an Adjuvant in the Treatment of COVID-19 Infection: A Review
Soares, S., Bornet, M., Grosso, C., Ramalhosa, M. J., Gouvinhas, I., Garcia, J., Rodrigues, F., & Delerue-Matos, C. M. (2022) · Applied Sciences · doi:10.3390/app12157800 · Cited by 17
Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations
Jitobaom, K., Boonarkart, C., Manopwisedjaroen, S., Punyadee, N., Borwornpinyo, S., Thitithanyanont, A., Avirutnan, P., & Auewarakul, P. (2022) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-022-00580-8 · Cited by 17
Karolyi, M., Pawelka, E., Omid, S., König, F., Kauer, V., Rumpf, B., Hoepler, W., Kuran, A., Laferl, H., Seitz, T., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.870493 · Cited by 17
Unethical studies of ivermectin for covid-19
Meyerowitz‐Katz, G., Wieten, S. E., Arellano, M. D. J. M., & Yamey, G. (2022) · BMJ · doi:10.1136/bmj.o917 · Cited by 16
A Peek into Pandora’s Box: COVID-19 and Neurodegeneration
Chandra, A., & Johri, A. (2022) · Brain Sciences · doi:10.3390/brainsci12020190 · Cited by 16
Padilha, D. A., Filho, V. B., Moreira, R. S., Soratto, T. A. T., Maia, G. A., Christoff, A. P., Barazzetti, F. H., Schörner, M. A., Ferrari, F. L., Martins, C. L., et al. (2022) · Viruses · doi:10.3390/v14040695 · Cited by 15
SIT1 transporter as a potential novel target in treatment of COVID-19
Semiz, S. (2021) · BioMolecular Concepts · doi:10.1515/bmc-2021-0017 · Cited by 15
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Rothrock, S. G., Weber, K. D., Giordano, P. A., & Barneck, M. D. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001461 · Cited by 14
Kapusta, J., Chudzik, M., Kałuzińska‐Kołat, Ż., Kołat, D., Burzyńska, M., Jankowski, P., & Babicki, M. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.008 · Cited by 14
Perspective: repurposed Drugs for COVID-19
Na‐Bangchang, K., Porasuphatana, S., & Karbwang, J. (2022) · Archives of Medical Science · doi:10.5114/aoms/152467 · Cited by 13
Wimalawansa, S. J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e34691 · Cited by 12
Angkasekwinai, N., Rattanaumpawan, P., Chayakulkeeree, M., Phoompoung, P., Koomanachai, P., Chantarasut, S., Wangchinda, W., Srinonprasert, V., & Thamlikitkul, V. (2022) · Antibiotics · doi:10.3390/antibiotics11060796 · Cited by 12
Domínguez, J. A. R., Mino‐León, D., & Wirtz, V. J. (2023) · BMJ Global Health · doi:10.1136/bmjgh-2022-010962 · Cited by 12
Ivermectin and the Integrity of Healthcare Evidence During COVID-19
O’Mathúna, D. P. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.788972 · Cited by 12
Hernández, A. V., Liu, A., Roman, Y. M., Burela, P. A., Pasupuleti, V., Thota, P., Carranza-Tamayo, C. O., Palacios, M. R. R., Benites-Zapata, V. A., Piscoya, A., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107248 · Cited by 12
Kunzler, A. M., Iannizzi, C., Burns, J., Metzendorf, M., Voigt-Radloff, S., Piechotta, V., Schmaderer, C., Holzmann‐Littig, C., Balzer, F., Benstoem, C., et al. (2024) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2024.111456 · Cited by 12
Self-citationKotra, V., Mallem, D., Kanuri, A. K., Burra, M. R., Nyamathulla, S., Ying, L. S., Husain, K., Varala, R., Madhavedi, S., Goh, K. W., et al. (2022) · Progress In Microbes & Molecular Biology · doi:10.36877/pmmb.a0000323 · Cited by 12
Long-term consequences of the misuse of ivermectin data
Alvarez-Moreno, C., Cassell, J., Donkor, C. M., Head, M., Middleton, J., Pomat, W., Saka, B., & Yirgu, R. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00630-7 · Cited by 11
Metzendorf, M., Weibel, S., Reis, S., & McDonald, S. J. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2022-112019 · Cited by 10
Self-citationCastaño-García, M., Granero‐Molina, J., Fernández‐Férez, A., Fernández‐Medina, I. M., Ventura‐Miranda, M. I., & Jiménez‐Lasserrotte, M. D. M. (2024) · Healthcare · doi:10.3390/healthcare12020162 · Cited by 10
Sattler, S., van Veen, F., Hasselhorn, F. A., Tabei, L. E., Fuhr, U., & Mehlkop, G. (2024) · Deviant Behavior · doi:10.1080/01639625.2024.2334274 · Cited by 10
Ivermectin's Role in the Prevention of COVID‐19: A Systematic Review and Meta‐Analysis
Hu, G., Liang, C., Lin, P., & Lin, C. (2022) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2178 · Cited by 10
Systematic Down-Selection of Repurposed Drug Candidates for COVID-19
MacRaild, C. A., Mohammed, M.-U.-R., Faheem, F., Murugesan, S., Styles, I. K., Peterson, A. L., Kirkpatrick, C. M. J., Cooper, M. A., Palombo, E. A., Simpson, M. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911851 · Cited by 10
Clinical Evaluation of a New Antigen-Based COVID-19 Rapid Diagnostic Test from Symptomatic Patients
Sazed, S. A., Kibria, M. G., Hossain, M. S., Zamil, M. F., Adhikary, P. C., Hossain, M. E., Ahmed, D., Haque, R., & Alam, M. S. (2021) · Diagnostics · doi:10.3390/diagnostics11122300 · Cited by 10
Disciplining Physicians Who Spread Medical Misinformation
Yang, Y. T., & DeRoo, S. S. (2022) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000001616 · Cited by 10
Uematsu, T., Takano, T., Matsui, H., Kobayashi, N., Ōmura, S., & Hanaki, H. (2023) · The Journal of Antibiotics · doi:10.1038/s41429-023-00623-0 · Cited by 9
Khan, M. U. A., Akhtar, T., Naseem, N., Aftab, U., Hussain, S., & Shahzad, M. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12902 · Cited by 9
Mind the Guardrails: Epistemic Trespassing and Apt Deference
Levy, N. L., & Varley, R. S. (2024) · Social Epistemology · doi:10.1080/02691728.2024.2400560 · Cited by 9
Satyam, S. M., El-Tanani, M., Patni, M. A., Rehman, A., Wali, A. F., Rangraze, I. R., Babiker, R., Rabbani, S. A., El-Tanani, Y., & Rizzo, M. (2025) · Antibiotics · doi:10.3390/antibiotics14050459 · Cited by 9
“While previous systematic reviews, including the comprehensive analysis by Popp et al. [49], have evaluated the efficacy and safety of ivermectin in COVID-19, they primarily concluded there was insufficient evidence to support its routine use.”
Scoy, L. J. V., Duda, S., Scott, A. M., Baker, A., Costigan, H. J., Loeffler, M., Sherman, M. S., & Brown, M. D. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.102104 · Cited by 9
Zebrafish behavioral response to ivermectin: insights into potential neurological risk
Powrie, Y. S. L., Strydom, M. A., Aucamp, M. E., Schellack, N., Steenkamp, V., & Smith, C. (2022) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2022.100141 · Cited by 9
Kuo, H.-W., Zure, D., & Lin, C.-R. (2023) · Chemosphere · doi:10.1016/j.chemosphere.2023.138713 · Cited by 9
Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Rothrock, S. G., Weber, K. D., Giordano, P., & Barneck, M. D. (2022) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001477 · Cited by 8
The impact of ivermectin on COVID-19 outcomes: a systematic review and meta-analysis
Yengu, N. S., Raheem, A., Pons, A. G., Ho, W. L., Ali, S. M. S., Haseeb, A., Ahmad, T. K. F., & Mustafa, M. S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000002762 · Cited by 8
Das, K., Das, P., Almuqbil, M. S., Asdaq, S. M. B., Nikhil, K., Preethi, K., Angelinkiruba, A., Alomar, N. F., harbi, R. M. A., Abdullah, W. A. A., et al. (2023) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2022.102534 · Cited by 8
Wada, T., Hibino, M., Aono, H., Kyoda, S., Iwadate, Y., Shishido, E., Ikeda, K., Kinoshita, N., Matsuda, Y., Otani, S., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1139046 · Cited by 6
Ho, M. K. H., Tadrous, M., Iacono, A., Suda, K. J., & Gomes, T. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac382 · Cited by 6
Mekky, R. Y., Elemam, N. M., Eltahtawy, O., Zeinelabdeen, Y. A., & Youness, R. A. (2022) · Life · doi:10.3390/life12101654 · Cited by 6
Recommendations for the outpatient drug treatment of patients with COVID-19
Kaduszkiewicz, H., Kochen, M. M., Kluge, S., Malin, J. J., Weibel, S., & Skoetz, N. (2022) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2022.0203 · Cited by 6
Self-citationTran, A., Sheikhan, N. Y., Sheikhan, T., Nowak, D. A., & Witek, T. J. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00109-6 · Cited by 6
Silva, K. D., Turner, T., & McDonald, S. J. (2025) · Cochrane Evidence Synthesis and Methods · doi:10.1002/cesm.70024 · Cited by 5
Mnkandla, M. M. A., Tshitangano, T. G., & Mudau, A. G. (2023) · Social Sciences · doi:10.3390/socsci12080464 · Cited by 5
Hashemi, H., Ghareghani, S., Nasimi, N., Shahbazi, M., Derakhshan, Z., & Sarkodie, S. A. (2022) · Sustainability · doi:10.3390/su142013614 · Cited by 5
When Desperate Patients Go to Court for Unproven Treatments — The Battle for Hospital Independence
Robertson, C. T., & Houtz, M. (2022) · New England Journal of Medicine · doi:10.1056/nejmp2200209 · Cited by 5
Qabbus, M. B., Hunt, K. S., Dynka, J., Woodworth, C. D., Sur, S., & Samways, D. S. K. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.116073 · Cited by 5
COVID-19 and Kidney Transplantation
Liriano-Ward, L. E., Azzi, Y. A., & Akalin, E. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00272022 · Cited by 5
Qi, Q., Pang, J., Chen, Y., Tang, Y., Wang, H., Gul, S., Sun, Y., Tang, W., & Sheng, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011232 · Cited by 4
Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients
Sigler, R., Chen, V., & Law, N. (2022) · Current Transplantation Reports · doi:10.1007/s40472-022-00368-z · Cited by 4
Gaboreau, Y., Milovančev, A., Rolland, C., Eychenne, C., Alcaraz, J., Salomez‐Ihl, C., Mazet, R., Boucher, F. R., Vermorel, C., Ostojić, S. M., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154308 · Cited by 4
Santos, S. F. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2022.tde-03102022-092552 · Cited by 4
Bryant, A., Lawrie, T. A., Fordham, E. J., & Mitchell, S. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001465 · Cited by 3
Anesi, G. L., Degnan, K. O., Dutcher, L. S., Saw, S., Maguire, C., Binkley, A., Patel, S. R., Athans, V., Barton, T. D., Binkley, S., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad428 · Cited by 3
Few More Lessons Learnt from Covid-19: Health Technology Assessment (HTA) Perspective
Khan, I. A., & Malik, N. (2022) · National Journal of Community Medicine · doi:10.55489/njcm.130820222103 · Cited by 3
Lai, C., Toriumi, F., & Yoshida, M. (2023) · Scientific Reports · doi:10.1038/s41598-023-41760-8 · Cited by 3
Webster‐Kerr, K., Grant, A. S., Harris, A., Thorpe, R., Rowe, D., Henningham, D., Mullings, T., Wellington, I., Wiggan, J., Gordon-Johnson, K.-A., et al. (2024) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2024.36 · Cited by 3
Llenas‐García, J., del Pozo, A., Talaya, A., Roig, N., Ruiz, N. P., García, C. D., Brunete, E. B., Cuello, I. G., Dato, A. L., Navarro, M., et al. (2023) · Viruses · doi:10.3390/v15051138 · Cited by 3
COVID-19 and a Tale of Three Drugs: To Repurpose, or Not to Repurpose–That Was the Question
Triggle, C. R., & MacDonald, R. S. (2025) · Viruses · doi:10.3390/v17070881 · Cited by 2
Swart, B., Ahiskali, A., Wolf, J. M., & Shaughnessy, M. K. (2023) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.23-0121 · Cited by 2
How Likes and Retweets Impacted Our Patients During the COVID-19 Pandemic
Ramirez, L. G., Wickner, P. G., Cline, N. B., Rehman, N., Wu, A. C., Pien, L. C., & Stukus, D. R. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.07.033 · Cited by 2
Catania, L. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-95187-6.00001-7 · Cited by 2
Acute management of COVID-19 in the emergency department: An evidence-based review
Abhilash, K. P. P., David, S., Joseph, E. S., & Peter, J. V. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1309_21 · Cited by 2
Goodbye, 2021: a year of failures interspersed with remarkable triumphs
Talley, N. J. (2021) · The Medical Journal of Australia · doi:10.5694/mja2.51345 · Cited by 2
Fatores prognósticos para pacientes com SARS-Cov
da Costa, L. A. T. J., Santos, S. S., Baltazar, L. T., Guimarães, C. S., Stabile, A. M., & Margatho, A. S. (2022) · Conjecturas · doi:10.53660/conj-2069-2s51a · Cited by 2
Fidahić, M., Nujić, D., Čivljak, M., Runjić, R., Markotić, F., Viđak, M., & Puljak, L. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01646-1 · Cited by 2
Fuenmayor-González, L., Rivadeneira, J., Jácome-García, M., Flores-Lastra, N., Otzen, T., Manterola, C., & Maldonado, J. C. (2025) · Pharmacy Practice · doi:10.18549/pharmpract.2025.1.3080 · Cited by 2
Ivermectin: An Effective Remedy Against Various Diseases: A Literature Review
Gholami, M. H., Hashemi, F., & Entezari, M. (2023) · Archives of Advances in Biosciences · doi:10.22037/aab.v13i.35552 · Cited by 2
Metadata
- Authors
- Popp, M., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S.
- Affiliations
- Universitätsklinikum Würzburg (DE)
- Humboldt-Universität zu Berlin (DE)
- Cochrane Canada (CA)
- University of Cologne (DE)
- ORCID
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2021-04-20
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC8078284
- OpenAlex
- W4206726277
- Semantic Scholar
- e91c416601c12a367657bbf3901c8729066d47ea
- Cited by
- 31
- References
- 30
- Citations by year
- 2026: 3 · 2024: 4 · 2023: 7 · 2022: 13 · 2021: 4
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Update notices
- new_version (2021-07-28)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- LSTM Online Archive (Liverpool School of Tropical Medicine) (acceptedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Keywords
- ivermectin, COVID-19 pandemic, SARS-CoV-2, antiviral therapy, post-exposure prophylaxis, COVID-19 prevention, COVID-19 treatment, antiparasitic drugs, viral clearance, mortality, adverse events, quality of life, length of hospital stay, risk of bias, quality of evidence, treatment efficacy and safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.